BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the RUCAPANC (Rucaparib Assessment in BRCA-mutated Pancreatic Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rucaparib is the Company’s oral, potent, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed for the treatment of pancreatic cancer and platinum-sensitive ovarian cancer.
Help employers find you! Check out all the jobs and post your resume.
